PVI
APRE icon

Pura Vida Investments’s Aprea Therapeutics APRE Stock Holding History

Pura Vida Investments’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,693
Closed -$1.25M – 234
2021
Q4 		$1.25M Buy
+21,693
New +$1.92M 0.05% 166

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Pura Vida Investments's APRE Position: Q1 2022 in Review

Pura Vida Investments sold out of Aprea Therapeutics (APRE) in Q1 2022, closing a stake of 21,693 shares — an estimated $1.25M sold.

Pura Vida Investments first reported a position in APRE in Q4 2021 and held it in 1 quarter. The position peaked at $1.25M in Q4 2021. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

  • Pura Vida Investments reported no remaining Aprea Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 21,693 Aprea Therapeutics shares in Q1 2022, an estimated $1.25M.
  • Pura Vida Investments first reported a position in Aprea Therapeutics in Q4 2021 and held it in 1 quarter.
  • Pura Vida Investments's Aprea Therapeutics position peaked at $1.25M in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.